Rockwell Medical (NASDAQ:RMTI) Rating Increased to Strong-Buy at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Rockwell Medical (NASDAQ:RMTI) to a strong-buy rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on RMTI. Rodman & Renshaw started coverage on Rockwell Medical in a research note on Thursday. They issued a “buy” rating and a $5.00 price objective for the company. StockNews.com raised Rockwell Medical from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Rockwell Medical in a research note on Wednesday, September 11th.

Rockwell Medical Trading Down 2.0 %

RMTI stock traded down $0.05 during midday trading on Thursday, hitting $2.44. 753,121 shares of the company’s stock were exchanged, compared to its average volume of 362,909. The business has a 50-day simple moving average of $3.71 and a two-hundred day simple moving average of $2.60. The company has a current ratio of 2.41, a quick ratio of 1.60 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $78.86 million, a PE ratio of -46.20 and a beta of 1.50. Rockwell Medical has a 1-year low of $1.16 and a 1-year high of $5.15.

Rockwell Medical (NASDAQ:RMTI) last posted its earnings results on Tuesday, November 12th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.04. Rockwell Medical had a positive return on equity of 8.55% and a negative net margin of 1.25%. The company had revenue of $28.32 million during the quarter, compared to analysts’ expectations of $25.99 million. On average, sell-side analysts predict that Rockwell Medical will post -0.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Concurrent Investment Advisors LLC acquired a new position in Rockwell Medical during the 3rd quarter worth $40,000. Verus Capital Partners LLC purchased a new stake in Rockwell Medical during the 3rd quarter worth about $51,000. Beacon Financial Advisory LLC purchased a new stake in Rockwell Medical during the 3rd quarter worth about $98,000. HighTower Advisors LLC lifted its holdings in Rockwell Medical by 75.6% during the 3rd quarter. HighTower Advisors LLC now owns 57,413 shares of the company’s stock worth $228,000 after buying an additional 24,715 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Rockwell Medical by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock worth $1,856,000 after buying an additional 43,302 shares during the last quarter. 23.31% of the stock is owned by institutional investors and hedge funds.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.